Clinical trial
A Research Study for Patients With Metastatic Renal Cell Carcinoma
NCT00106613 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00106613 |
|---|---|
| Title | A Research Study for Patients With Metastatic Renal Cell Carcinoma |
| Official title | An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Patients With Metastatic Renal Cell Carcinoma That is Progressive Following or During Immunotherapy |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | FK228 (romidepsin) |
| Enrollment | 30 |
| Start date | May 1, 2003 |
| Primary completion | Aug 1, 2004 |
| Completion | Aug 1, 2004 |
| First posted | Mar 29, 2005 |
| Last update posted | Oct 18, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: